Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population studyAntonietta Romano, A. Albertí, Paolo Angeli et al.|Journal of Hepatology|2018Cited by 166
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, S. Fagiuoli, Massimo Puoti et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 19
THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 3
Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP surveySavino Bruno, V. Di Marco, S. Bollani et al.|Digestive and Liver Disease|2014Cited by 1
Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Digestive and Liver Disease|2019Cited by 1